EANS-News: AGENNIX AG / Agennix AG Announces Issuance of U.S. Patent Covering Use of Talactoferrin to Treat Non-Small Cell Lung Cancer and Renal Cell Carcinoma

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston,
TX, March 23, 2011 - Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX)
today announced that the U.S. Patent and Trademark Office has issued patent
number 7,901,879, entitled, "Lactoferrin in the treatment of malignant neoplasms
and other hyperproliferative diseases." The patent, which has a term until
2025, covers the use of oral human lactoferrins, including talactoferrin, for
the treatment of non-small cell lung cancer (NSCLC) and renal cell carcinoma.

Torsten Hombeck, Ph.D., Chief Financial Officer and member of the Company's
Management Board, said: "This patent further strengthens our intellectual
property position for talactoferrin in a key market and, importantly, covers the
use of talactoferrin in its lead indication, non-small cell lung cancer. We are
pleased to have recently completed enrollment in the FORTIS-M Phase III
registration trial evaluating talactoferrin for this use."

Agennix also reported that a patent application covering the use of
talactoferrin in lung cancer has recently received a Decision to Grant in Japan.
This patent would provide protection until 2023. The Company has a patent
application pending in Europe related to the use of talactoferrin in oncology.

About talactoferrin
Talactoferrin is an oral biologic therapy with immunomodulatory and
antibacterial properties, which is being studied for the treatment of cancer and
severe sepsis. Talactoferrin has demonstrated promising activity in randomized,
double-blind, placebo-controlled Phase II studies in NSCLC, as well as in severe
sepsis. Two Phase III trials with talactoferrin in NSCLC are ongoing, and one -
the FORTIS-M trial -completed enrollment in March 2011. NSCLC is one of the
most common types of cancer worldwide and the most frequent cause of cancer
death. Agennix also plans to develop talactoferrin further for the treatment of
severe sepsis and plans to initiate a Phase II/III trial in that indication.
Talactoferrin has been shown to be very well tolerated in these patient
populations.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral therapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as well as in
severe sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program further
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical
gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. There can be no
guarantee that talactoferrin will be approved for marketing for non-small cell
lung cancer or any other indication in a timely manner, if at all.
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
[email protected]

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
[email protected]

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
[email protected]

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: [email protected]
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print